Speclips, a company specializing in laser and artificial intelligence (AI)-based skin diagnosis and treatment solutions, announced on the 10th that it participated in the International Congress of Aesthetic Plastic Surgery (IMCAS) Asia 2025 held in Bangkok, Thailand from June 6th to 8th and carried out activities to expand its market in the Asian region.
At this exhibition, Speclips introduced its skin beauty and treatment medical devices, ‘PICO-K’ and ‘BELLUS-Q’, and directly demonstrated the technological prowess of its products to on-site medical staff and buyers through constant product demonstrations within the booth. In addition, it supported academic presentations by local medical staff on the topic of ‘skin regeneration treatment using picosecond laser’, thereby increasing interest in the potential use of the products and their clinical effectiveness.
During the exhibition, Speclips discussed expanding cooperation with existing partners in Thailand and also focused on strengthening cooperative relationships with buyers in neighboring countries such as Malaysia and Singapore. The company plans to accelerate the diversification of global sales channels in the future by expanding its network with emerging markets in Southeast Asia such as India, Indonesia, and the Philippines.
The flagship product, Pico-K, is a medical device specialized in improving pigment diseases and skin regeneration using a high-power laser of 300 picoseconds. It has recorded sales of over 100 units in the Taiwanese market in 2024, the first year of its launch, and is increasing brand awareness through marketing activities. BellusQ is a high-power nanosecond laser device that supports various pulse modes, and is characterized by its ability to provide customized treatment according to skin type and lesion depth.
It is also pushing to enter the US market. Speclipse is working with local partners to conduct preliminary procedures such as product testing, selecting key doctors, and preparing related papers, with the goal of obtaining US Food and Drug Administration (FDA) approval in early 2026. It is also speeding up the process of securing certification such as quality inspection.
In addition, with the recent acquisition of Russian medical device approval along with European CE certification, a multinational export strategy including Europe and the Commonwealth of Independent States (CIS) region is also being launched in earnest.
CEO Hong Jeong-hwan said, “Through this participation in IMCAS Asia, we have created an opportunity to increase brand awareness and reliability in the Asian market,” and “After FDA approval, we will continue to expand our contact points with global customers by participating in IMCAS World 2026.” He added, “We will make 2025 a strategic starting point for global market expansion and accelerate our entry into major overseas markets, including emerging countries.”
- See more related articles
You must be logged in to post a comment.